Eli Lilly announced plans to increase drug list prices in Europe, including a triple price hike for its obesity drug Mounjaro in the UK, aiming to offset US pricing pressures linked to the Trump administration’s push for lower domestic costs. This 'rebalancing' strategy to align prices globally reflects the shifting dynamics in pharmaceutical pricing policies and regulatory actions, raising questions about the net financial impact and market reactions.